Biological
Serogroup C meningococcal conjugate vaccine clinical trials
- studies test it
- 11
- open now
- 0
- in phase 3
- 5
- first study started
- 2004
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2005 (4)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 1 |
| 2008 | 2 |
| 2010 | 1 |
| 2013 | 1 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 5
- Phase 4
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 2
Novartis Vaccines (3) · Novartis (3) · Public Health England (2) · Pfizer (2) · GlaxoSmithKline (1)
Often tested with
Tested in the same studies.
Neisseria meningitidis group C (strain C11) oligosaccharide CRM-197 adipic acid conjugate (2) · Haemophilus Vaccines (1) · Meningococcal Vaccines (1) · Rabies Vaccines (1) · Heptavalent Pneumococcal Conjugate Vaccine (1)
Studies
Open first, then newest update. How each study uses serogroup C meningococcal conjugate vaccine is read from its arms, and is right about nine times in ten.
Testing it · 11
- Hepatitis B Vaccination in InfantsCompletedPhase 4Public Health EnglandNCT01896596Written as NeisVac-C
- An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in AfricaCompletedPhase 3GlaxoSmithKlineNCT02207816Written as Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)
- Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of LifeCompletedPhase 4Public Health EnglandNCT00625677Written as NeisVacC (Meningococcal C conjugate vaccine)
- Persistence of Antibody Response to N. Meningitidis Group C in ChildrenCompletedPhase 4Novartis VaccinesNCT00316654Written as Meningococcal C conjugate vaccine
- Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With PCV7 (Prevenar®)CompletedPhase 3PfizerNCT00617760Written as Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT)
- NeisVac-C Single Prime Study in InfantsCompletedPhase 3PfizerNCT01218451Written as Meningococcal group C polysaccharide conjugate vaccine
- Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC VaccineCompletedPhase 4Novartis VaccinesNCT00310713Written as Meningococcal C conjugate vaccine
- Kinetics of B Cell Response in Infants Menjugate VaccinationCompletedPhase 4NovartisNCT00310700Written as Meningococcal C conjugate vaccine
- Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy ChildrenCompletedPhase 3Novartis VaccinesNCT00311415Written as Meningococcal C conjugate vaccine
- Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of AgeCompletedPhase 3NovartisNCT00310674Written as Meningococcal C Conjugate Vaccine
- Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of AgeCompletedPhase 4NovartisNCT00310635Written as Meningococcal C conjugate vaccine
Given in every arm · 8 — serogroup C meningococcal conjugate vaccine is usual care beside what is tested
- Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same VaccinesCompletedPhase 3GlaxoSmithKlineNCT00463437Written as NeisVac-C
- Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in AfricaCompletedPhase 3GlaxoSmithKlineNCT00866619Written as Meningococcal C Conjugate Vaccine
- Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)CompletedPhase 3MCM Vaccines B.V.NCT01553279Written as MCC-TT
- Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)CompletedPhase 3MCM Vaccines B.V.NCT01839188Written as NeisVac-C®
- Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)CompletedPhase 2Novartis VaccinesNCT00310856Written as MenC-CRM
- RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)CompletedPhase 3Merck Sharp & Dohme LLCNCT00443846Written as NeisVac-C®
- Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster VaccinationCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT01839175Written as NeisVac-C
- Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in InfantsCompletedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00384059Written as NeisVac-C
As the comparator · 3 — what is tested is compared with serogroup C meningococcal conjugate vaccine
- Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European ToddlersCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03890367Written as Meningococcal group C polysaccharide Conjugate vaccine adsorbed
- Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster DoseCompletedPhase 2GlaxoSmithKlineNCT01171989Written as NeisVac-C™
- Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenCCompletedPhase 3GlaxoSmithKlineNCT00322335Written as NeisVac-C™